BCL2L1 and non-Hodgkin lymphoma: To assess the contribution of BCL-XL for survival, we treated all NHL cell lines with BCL-XL-selective inhibitor A-1155463.31 As expected, BCL2High cell lines were resistant to the BCL-XL-selective inhibitor A-1155463 (EC50 >5 μM).